{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:39:00Z","timestamp":1792521540508,"version":"4.5.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an important role in pathogenesis, as shown by successful treatment with immunosuppressive agents, leading to transfusion independence or complete recovery of peripheral blood counts in a proportion of patients. Growth factors can be combined with immunosuppressive therapy (IST) and may improve response rates, as recently shown with thrombopoietin analogs. Anabolic steroids may still play a role in combination with IST. The problem with IST is failure to respond and the development of late clonal disorders. Bone marrow transplantation (BMT) is the other therapeutic option: a matched sibling donor remains the best choice. For patients lacking a matched family donor, unrelated donors can be readily found, although mostly for patients of Caucasian origin. Other BMT options include unrelated cord blood or mismatched family donors. Acute and chronic graft-versus-host disease remain important complications of BMT. Patient age is a strong predictor of outcome for both IST and BMT, and must be considered when designing therapeutic strategies. Early diagnosis and treatment, as well as long-term monitoring, remain crucial steps for successful treatment of SAA.<\/jats:p>","DOI":"10.1182\/blood-2016-08-693481","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T22:01:14Z","timestamp":1484690474000},"page":"1428-1436","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":383,"title":["How I treat acquired aplastic anemia"],"prefix":"10.1182","volume":"129","author":[{"given":"Andrea","family":"Bacigalupo","sequence":"first","affiliation":[{"name":"Istituto di Ematologia, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111904084400700_B1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111904084400700_B2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1989.tb00230.x","article-title":"Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin","volume":"73","author":"de Planque","year":"1989","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111904084400700_B3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM199105093241909","article-title":"Immunosuppression in aplastic anemia--postponing the inevitable?","volume":"324","author":"Moore","year":"1991","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111904084400700_B4","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2014-05-526285","article-title":"Bone marrow failure and the telomeropathies","volume":"124","author":"Townsley","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111904084400700_B5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/leu.2013.30","article-title":"Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia","volume":"27","author":"Lane","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111904084400700_B6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111904084400700_B7","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111904084400700_B8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V45.3.355.bloodjournal453355","article-title":"Selection of patients for bone marrow transplantation in severe aplastic anemia","volume":"45","author":"Camitta","year":"1975","journal-title":"Blood"},{"issue":"9","key":"2019111904084400700_B9","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V99.9.3129","article-title":"Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia","volume":"99","author":"Maciejewski","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111904084400700_B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2141.1988.tb02460.x","article-title":"Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party","volume":"70","author":"Bacigalupo","year":"1988","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111904084400700_B11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0037-1963(00)90031-3","article-title":"Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience","volume":"37","author":"Bacigalupo","year":"2000","journal-title":"Semin Hematol"},{"issue":"1","key":"2019111904084400700_B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3324\/haematol.10075","article-title":"Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"92","author":"Locasciulli","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"2019111904084400700_B13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2012.220","article-title":"Supportive care in severe and very severe aplastic anemia","volume":"48","author":"H\u00f6chsmann","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111904084400700_B14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2010.08194.x","article-title":"Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party","volume":"149","author":"Locasciulli","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111904084400700_B15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111904084400700_B16","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3324\/haematol.2014.109355","article-title":"First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy","volume":"99","author":"Yoshida","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2019111904084400700_B17","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2010.026682","article-title":"Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors","volume":"95","author":"Gupta","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111904084400700_B18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood.V84.3.941.941","article-title":"Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia","volume":"84","author":"Storb","year":"1994","journal-title":"Blood"},{"issue":"10","key":"2019111904084400700_B19","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1182\/blood-2006-10-052308","article-title":"Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens","volume":"109","author":"Champlin","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2019111904084400700_B20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","article-title":"Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups","volume":"97","author":"Bacigalupo","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2019111904084400700_B21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2006.06019.x","article-title":"Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation","volume":"133","author":"Srinivasan","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111904084400700_B22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.bmt.1704785","article-title":"Fludarabine-based conditioning for allogeneic stem cell transplantation for multiply transfused patients with Fanconi\u2019s anemia","volume":"35","author":"George","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111904084400700_B23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.2006.06084.x","article-title":"Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen","volume":"133","author":"Resnick","year":"2006","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111904084400700_B24","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3324\/haematol.2009.006916","article-title":"Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen","volume":"94","author":"Maury","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"2019111904084400700_B25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/bmt.2012.223","article-title":"Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor","volume":"48","author":"Aljurf","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111904084400700_B26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111904084400700_B27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2007-03-081596","article-title":"Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia","volume":"110","author":"Schrezenmeier","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111904084400700_B28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.13614","article-title":"Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT","volume":"171","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111904084400700_B29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V100.3.799","article-title":"Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program","volume":"100","author":"Kojima","year":"2002","journal-title":"Blood"},{"key":"2019111904084400700_B30","doi-asserted-by":"crossref","article-title":"Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the Severe Aplastic Anemia Working Party of EBMT","author":"Devillier","DOI":"10.3324\/haematol.2015.138727"},{"issue":"14","key":"2019111904084400700_B31","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood-2012-03-417758","article-title":"Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders","volume":"120","author":"Horan","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111904084400700_B32","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood-2006-03-005041","article-title":"Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy","volume":"108","author":"Deeg","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111904084400700_B33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019111904084400700_B34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2014.115345","article-title":"Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis","volume":"100","author":"Bacigalupo","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2019111904084400700_B35","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2011-05-354001","article-title":"Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia","volume":"118","author":"Eapen","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111904084400700_B36","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2010-12-327536","article-title":"Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia","volume":"118","author":"Marsh","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111904084400700_B37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2009.018267","article-title":"Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party","volume":"95","author":"Bacigalupo","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111904084400700_B38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ajh.21355","article-title":"Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function","volume":"84","author":"Okuda","year":"2009","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111904084400700_B39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbmt.2006.04.005","article-title":"Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine","volume":"12","author":"Koh","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111904084400700_B40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/bbmt.2001.v7.pm11349807","article-title":"Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation","volume":"7","author":"Deeg","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111904084400700_B41","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(15)00147-7","article-title":"Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study","volume":"2","author":"Anderlini","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111904084400700_B42","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2015.139469","article-title":"Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia","volume":"101","author":"Arai","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2019111904084400700_B43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2010.06.011","article-title":"Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation","volume":"17","author":"Peffault de Latour","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111904084400700_B44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.scr.2013.10.001","article-title":"Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD","volume":"12","author":"Wu","year":"2014","journal-title":"Stem Cell Res (Amst)"},{"issue":"5","key":"2019111904084400700_B45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111904084400700_B46","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","article-title":"Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia","volume":"20","author":"Clay","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111904084400700_B47","doi-asserted-by":"crossref","first-page":"e89666","DOI":"10.1371\/journal.pone.0089666","article-title":"Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"2019111904084400700_B48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/bmt.2013.224","article-title":"Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy","volume":"49","author":"Gao","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111904084400700_B49","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bmt.2010.213","article-title":"Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia","volume":"46","author":"Dezern","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111904084400700_B50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2011.28","article-title":"In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT","volume":"47","author":"Dominietto","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111904084400700_B51","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/bmt.2009.296","article-title":"Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT","volume":"45","author":"Piccin","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2019111904084400700_B52","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJM199105093241901","article-title":"Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine","volume":"324","author":"Frickhofen","year":"1991","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111904084400700_B53","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058","article-title":"Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia","volume":"85","author":"Rosenfeld","year":"1995","journal-title":"Blood"},{"issue":"4","key":"2019111904084400700_B54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2008-1043875","article-title":"Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience","volume":"210","author":"F\u00fchrer","year":"1998","journal-title":"Klin Padiatr"},{"issue":"6","key":"2019111904084400700_B55","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood.V96.6.2049","article-title":"Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia","volume":"96","author":"Kojima","year":"2000","journal-title":"Blood"},{"issue":"9","key":"2019111904084400700_B56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3324\/haematol.2011.042622","article-title":"Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia","volume":"96","author":"Afable","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"2019111904084400700_B57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00277-015-2305-3","article-title":"Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis","volume":"94","author":"Vallejo","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111904084400700_B58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/08880018.2011.568043","article-title":"Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia","volume":"28","author":"Deyell","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"2019111904084400700_B59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2141.2007.06903.x","article-title":"Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up","volume":"140","author":"Saracco","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111904084400700_B60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111904084400700_B61","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2012-02-407684","article-title":"Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party","volume":"119","author":"Marsh","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111904084400700_B62","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2013.089268","article-title":"Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children","volume":"99","author":"Jeong","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2019111904084400700_B63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01378.x","article-title":"Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia","volume":"84","author":"Chang","year":"2010","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111904084400700_B64","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-012-1184-4","article-title":"Rabbit-antithymocyte globulin combined with cyclosporin A as a first-line therapy: improved, effective, and safe for children with acquired severe aplastic anemia","volume":"138","author":"Chen","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2019111904084400700_B65","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V95.6.1931","article-title":"Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO\/EBMT study on 100 patients","volume":"95","author":"Bacigalupo","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2019111904084400700_B66","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2141.2002.03947.x","article-title":"Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia","volume":"119","author":"Gluckman","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111904084400700_B67","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2006-11-050526","article-title":"Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan","volume":"110","author":"Teramura","year":"2007","journal-title":"Blood"},{"issue":"17","key":"2019111904084400700_B68","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","article-title":"A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation","volume":"117","author":"Tichelli","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111904084400700_B69","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2141.1998.01014.x","article-title":"Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults","volume":"103","author":"Kaito","year":"1998","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111904084400700_B70","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111904084400700_B71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.LBA-2.LBA-2","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia accelerates count recovery and increases response rates [abstract]","volume":"126","author":"Townsley","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111904084400700_B72","first-page":"391","article-title":"A study of the efficacy of 5 alpha- and 5 beta-androstanes in chronic experimental aplastic anemia in mice","volume":"26","author":"Najean","year":"1984","journal-title":"Nouv Rev Fr Hematol"},{"issue":"11","key":"2019111904084400700_B73","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood.V76.11.2222.2222","article-title":"Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias","volume":"76","author":"Najean","year":"1990","journal-title":"Blood"},{"issue":"1","key":"2019111904084400700_B74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V66.1.184.bloodjournal661184","article-title":"Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial","volume":"66","author":"Champlin","year":"1985","journal-title":"Blood"},{"issue":"1","key":"2019111904084400700_B75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.1993.tb04645.x","article-title":"Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party","volume":"83","author":"Bacigalupo","year":"1993","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111904084400700_B76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00277-006-0152-y","article-title":"Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens","volume":"85","author":"Leleu","year":"2006","journal-title":"Ann Hematol"},{"issue":"22","key":"2019111904084400700_B77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3900.3900","article-title":"Androgens may boost responses to anti-thymocyte globulin in acquired aplastic anemia [abstract]","volume":"128","author":"Giammarco","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111904084400700_B78","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2008-09-178871","article-title":"Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells","volume":"114","author":"Calado","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2019111904084400700_B79","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111904084400700_B80","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2009-06-225375","article-title":"High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up","volume":"115","author":"Brodsky","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111904084400700_B81","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1182\/blood-2014-05-573642","article-title":"Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution","volume":"124","author":"Scheinberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111904084400700_B82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1040-8428(99)00052-9","article-title":"Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria","volume":"33","author":"Boccuni","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2019111904084400700_B83","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2005-06-2485","article-title":"Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia","volume":"107","author":"Sugimori","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111904084400700_B84","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3324\/haematol.2015.132530","article-title":"Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia","volume":"100","author":"Narita","year":"2015","journal-title":"Haematologica"},{"key":"2019111904084400700_B85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/asheducation.V2000.1.18.20000018","article-title":"New insights into the pathophysiology of acquired cytopenias","volume":"2000","author":"Young","year":"2000","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"16","key":"2019111904084400700_B86","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM199310143291603","article-title":"Malignant tumors occurring after treatment of aplastic anemia","volume":"329","author":"Soci\u00e9","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111904084400700_B87","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3324\/haematol.2014.108977","article-title":"Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2019111904084400700_B88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7326\/0003-4819-130-3-199902020-00004","article-title":"Effectiveness of immunosuppressive therapy in older patients with aplastic anemia","volume":"130","author":"Tichelli","year":"1999","journal-title":"Ann Intern Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/11\/1428\/1399097\/blood693481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/11\/1428\/1399097\/blood693481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:10:09Z","timestamp":1574136609000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/11\/1428\/35931\/How-I-treat-acquired-aplastic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":88,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,3,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-693481","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727215403.793569269","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.727215403.793577868","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}